Equities

Elixinol Wellness Ltd

Elixinol Wellness Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.005
  • Today's Change0.00 / 0.00%
  • Shares traded221.56k
  • 1 Year change-64.79%
  • Beta2.5625
Data delayed at least 20 minutes, as of May 09 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Elixinol Wellness Limited is an Australia-based hemp company. The Company is engaged in marketing and selling hemp derived and other plant-based nutraceuticals, skincare and food products. In Australia, it operates a vertically integrated business, which produces, manufactures, and distributes a range of complementary products delivered across four verticals: human nutrition, human wellness, pet wellness and superfood ingredients. These products are sold under brands including Hemp Foods Australia, Mt Elephant and Field Day and are sold through grocery, wholesale, and e-commerce channels. In the Americas, it is engaged in marketing and selling quality Elixinol branded hemp and other plant-derived nutraceutical and skincare products based in Colorado, United States. In the United Kingdom, Japan, Brazil, Mexico and South Africa, branded hemp and other plant-derived products are available to consumers via exclusive distribution and/or trademark and know-how licensing agreements.

  • Revenue in AUD (TTM)8.48m
  • Net income in AUD-7.51m
  • Incorporated2017
  • Employees--
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
EXL:ASX since
announced
Transaction
value
Ananda Food Pty LtdDeal completed12 Feb 202412 Feb 2024Deal completed-50.00%1.96m
Data delayed at least 20 minutes, as of May 09 2024 07:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Innlanz Ltd2.60m-572.07k3.13m----1.27--1.21-0.0018-0.00180.00830.00790.32913.4431.98---7.25-19.94-10.11-27.6297.4884.14-22.03-21.260.3286-2.150.4858--65.72-40.0468.03---46.77--
Eve Health Group Ltd2.28m-1.99m5.27m----2.42--2.32-0.0004-0.00070.00040.00040.44622.2122.20---38.97-33.15-47.82-36.2830.6333.67-87.35-146.042.23-5,132.580.1348--16.00161.9454.10------
Aumake Ltd17.21m-3.00m5.74m171.00--1.06--0.3337-0.0024-0.00240.01180.00282.3018.1127.53---38.93-38.76-67.29-58.970.021430.59-16.96-32.430.9353--0.00---58.68-33.3250.12------
Elixinol Wellness Ltd8.48m-7.51m6.51m----0.6206--0.767-0.013-0.0130.01410.00810.67331.792.99---59.59-77.11-89.54-84.5942.8349.78-88.51-308.550.9044-55.430.1619--19.85-25.7428.98---67.79--
Oliver's Real Food Ltd25.22m-655.99k7.93m------7.070.3145-0.0016-0.00160.0607-0.03531.8915.56230.92---4.93-43.36-15.88-68.1263.9564.53-2.60-35.440.17480.27082.32--27.82-7.07150.48---49.45--
Star Combo Pharma Ltd25.66m485.16k19.59m--31.120.587315.860.76350.00470.00470.25920.24690.63534.767.87--1.20-7.361.30-8.2122.4316.091.89-10.724.325.180.1092--4.5018.05-474.85--27.39--
Data as of May 09 2024. Currency figures normalised to Elixinol Wellness Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.